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Abstract
In previous work we have documented the nuclear translocation of endothelial NOS (eNOS) and its participation in
combinatorial complexes with Estrogen Receptor Beta (ERb) and Hypoxia Inducible Factors (HIFs) that determine localized
chromatin remodeling in response to estrogen (E2) and hypoxia stimuli, resulting in transcriptional regulation of genes
associated with adverse prognosis in prostate cancer (PCa). To explore the role of nuclear eNOS in the acquisition of
aggressive phenotype in PCa, we performed ChIP-Sequencing on chromatin-associated eNOS from cells from a primary
tumor with poor outcome and from metastatic LNCaP cells. We found that: 1. the eNOS-bound regions (peaks) are widely
distributed across the genome encompassing multiple transcription factors binding sites, including Estrogen Response
Elements. 2. E2 increased the number of peaks, indicating hormone-dependent eNOS re-localization. 3. Peak distribution
was similar with/without E2 with < 55% of them in extragenic DNA regions and an intriguing involvement of the 59 domain
of several miRs deregulated in PCa. Numerous potentially novel eNOS-targeted genes have been identified suggesting that
eNOS participates in the regulation of large gene sets. The parallel finding of downregulation of a cluster of miRs, including
miR-34a, in PCa cells associated with poor outcome led us to unveil a molecular link between eNOS and SIRT1, an epigenetic
regulator of aging and tumorigenicity, negatively regulated by miR-34a and in turn activating eNOS. E2 potentiates miR-34a
downregulation thus enhancing SIRT1 expression, depicting a novel eNOS/SIRT1 interplay fine-tuned by E2-activated ER
signaling, and suggesting that eNOS may play an important role in aggressive PCa.
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Introduction
Nitric oxide (NO) and its synthases attained celebrity among
oncologists because of the evidence of frequent deregulation of
NO production in several tumors, including prostate cancer (PCa,
[1,2,3], and of the discovery of a key role played by the endothelial
NOS (eNOS) in tumor maintenance and progression [1,3,4]. Our
prior experimental results have provided demonstration of the
physiopathological role of eNOS in three cellular contexts: normal
human endothelial cells (HUVEC) before and after treatment with
17b-estradiol (E2); epithelial cell cultures from PCa explants grown
in basal condition or with E2; and prostate tissue specimens from
PCa patients. Confocal microscopy and immunohistochemistry
have documented, in particular, eNOS nuclear translocation in all
three experimental models [1,5] and provided the following
evidence: (i) eNOS-NO ‘nuclear’ signaling is a key pathway in
endothelial cell response to angiogenic stimuli and in the
acquisition of a more aggressive phenotype in PCa; and (ii) the
existence and functional role of crucial combinatorial complexes
on chromatin, eNOS/ERa specifically involved in the mainte-
nance of vascular homeostasis [6,7] and eNOS/ERb, eNOS/HIF-
1a or eNOS/HIF-2a specifically associated to adverse clinical
outcome of PCa [1]. In the tumor model, these complexes
determine localized remodeling of the chromatin in response to
estrogen and hypoxia stimuli, resulting in transcriptional regula-
tion of prognostic target genes [1]. Whether eNOS and its partners
are present as a constellation of coordinate complexes or in the
form of a macro-multifactorial complex remains to be evaluated.
In recent years, a relevant role in human cancer initiation,
progression and metastasis has been assigned also to dysregulation
of microRNAs (miRs) [8,9]. How the expression of prognostic
target genes is regulated in the context of PCa is currently under
investigation although several reports [10,11,12,13,14] have
identified clusters highly relevant for prostate cancer. Here we
have expanded on this aspect by documenting a significant
downregulation of a cluster of miRs, exclusively in PCa cells
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comprises miR-34a, the first miR identified as a regulator of the
SIRT1 deacetylase [15] a critical epigenetic controller of aging
and tumorigenicity [16].
Of note eNOS and NO have also been involved in the aging
process, a relevant observation since aging is considered an
independent risk factor in several pathological conditions. During
aging, eNOS is often deregulated and the usual NO biosynthesis
transformed to production of free radicals. This effect contributes
to DNA damage and genomic instability providing a favorable
ground for cancer development. Indeed eNOS has been recently
associated to maintenance of pancreatic cancer [4] and to
progression of PCa [1], one of the most common cancer in the
elderly. Interestingly, the role of eNOS during the aging process is
strictly linked to the function of SIRT1. In physiological
conditions, SIRT1 activates eNOS by deacetylation. Aging, by
impairing SIRT1 function determines a reduced glucose metabolic
efficiency as well as a reduced production of appropriate NO
levels, thus deteriorating the intracellular environment.
These premises together with our original finding that the NO
pathway represents a ‘‘primum movens’’ of a transcriptional program
promoting the acquisition of an aggressive phenotype in PCa cells,
and that the nuclear translocation of eNOS significantly affects
chromatin remodeling of a specific subset of PCa prognostic genes
[17], has prompted us to investigate the full potential of this key
signaling molecule as master gene in the progression of prostate
cancer. Our aim and challenge were to unmask the function of
eNOS on a genome-wide scale by a ChIP-Sequencing approach,
with the hope of unveiling a general mechanism associated with
the presence of nuclear eNOS in prostate tumors. Here we present
experimental evidence that defines a molecular circuitry that
contributes to aggressive and metastatic PCa and can be
modulated by eNOS or SIRT1 inhibitors with potential impact
on current therapies for PCa.
Methods
Hormones and Inhibitors
17b-Estradiol (E2 Sigma), NG-nitro-L-arginine methyl ester (L-
NAME; Alexis), TSA (Sigma-Aldrich), MS275, MC1568, sirtinol,
resveratrol were a kind gift of Antonello Mai (Rome, Italy).
Antibodies
anti–ERa (HC-20 [Santa Cruz Biotechnology]; anti–ERb (L-20
[Santa Cruz Biotechnology], anti-eNOS (eNOS/NOS Type III
[BD Biosciences]; abcam, Cambridge, UK and Cell Signaling,
MA,USA), anti-HDAC1 (abcam, Cambridge, UK and Sigma-
Aldrich, MO, USA), anti-HDAC2 (Santa Cruz Biotechnology,
CA, USA), anti-HDAC3 (Santa Cruz Biotechnology, CA, USA),
anti-HDAC4 (abcam, Cambridge, UK and Santa Cruz, CA,
USA); anti-HDAC5 (abcam, Cambridge, UK) anti-SIRT1
(abcam, Cambridge, UK); anti-IgG (Santa Cruz Biotechnology,
CA, USA), anti-5-methylcytidine (Eurogentec, Seraing, Belgium),
anti-a-actin (Sigma-Aldrich), and anti-HSP70 (StressGen Biotech-
nologies, San Diego, CA).
Cell Culture
HUVEC and LNCaP cells were cultured as described [1,5].
Primary prostate cancer cultures were obtained from freshly
explanted prostate cancer specimens upon approval of the
Institutional Ethical Committee as described [17]. Immortalized
PCa-cells were obtained by transduction of hTERT and SV40
large T antigen as described [1]. Clinical data of patients included
in the present study have already been reported elsewhere [17].
The outcome of patients (survival, metastasis, local and/or
biochemical recurrence) was followed up to December 2012
(observation period, July 2002 to December 2012). Bad prognosis
group (G1) of patients with PCa was defined by the presence of
biochemical/local recurrence, metastasis, or disease-specific mor-
tality, and Good prognosis group (G2) was defined by complete
remission with surgery alone. Cell lines derived from patients have
been assigned correspondingly to the G1 (C1IM, C11IM, C13IM,
C19IM, C27IM, C43IM, C45IM) or G2 (C14IM, C24IM,
C25IM, C35IM, C38IM, C39IM, C40IM, C41IM) phenotypes.
Transfections, Cell Extracts and Western Blot
Transient transfections were performed by the Jet Pei
TM
technique (Poly Plus Transfection). eNOS vector encoding
S1177A was a gift from C.M. Counter (Duke University Medical
Center, Durham, USA) [4]. Total extracts for Co-IP immuno-
precipitation were obtained with USA Buffer (Tris-Hcl 50 mM
pH=7.5; EDTA 5 mM; NaCl 250 mM; Triton 0.1%; NaF
50 mM ), nuclear and cytoplasmic fractions were obtained as
previously described [18].
Treatments
Cells were treated with 10
27 M E2, 5 mM L-NAME, 500 nM
TSA, 500 nM MS275, 10 mM MC1568, 10 mM sirtinol, 25 mM
resveratrol, alone or in combination for the times indicated in
figure legends. At least 72 hours prior to experimental use, the cells
were switched to medium supplemented with hormone-deprived
serum [19].
ChIPs and Re-ChIPs
ChIP and re-ChIP assays from cultured cells were performed as
described [1] using specific antibodies to ERb, eNOS, SIRT1,
HDAC1, HDAC 3, HDAC 4. Negative controls were absence of
antibody (NoAb) or normal IgG. Analysis of methylation using
antibody anti-5-methylcytidine was performed as described in [5].
DNA fragments were recovered and analyzed by quantitative
Real-time PCR as described [1]. Primers are presented in the
supplemental section.
For ChIP-sequencing, ChIPs were performed as described [1,6]
with modifications. Briefly, chromatin solutions were prepared by
sonication using Bioruptor UCD-200 (Diagenode) to obtain DNA
fragments between 150–500 bps in length. Pre-clearing of
chromatin solution was performed with protein G-agarose (Pierce)
and recovery of immune complexes with protein G saturated with
BSA at a final concentration of 1 mg/ml. Immunoprecipitated and
input DNA samples were dissolved in double distilled H2O.
Validation of DNA prior to sequencing was performed by qPCR
using primers specific for the hTERT and pS2 promoters (see
Supplemental section).
Library Preparation, ChIP-Sequencing and Bioinformatic
Analysis
NGS library preparation and SOLiD sequencing were per-
formed at Genomnia. DNA samples in 50 ml of Tris-HCl 10 mM,
EDTA 1 mM, pH 8 were sheared using the Covaris
TM S2
System, with the following settings: duty cycle 10%, intensity 5%,
cycles/burst 200, cycle time 60 s, number of cycles 3. DNA size
after shearing, checked on Bioanalyzer, was 25–400 nt with a peak
around 140 nt. Sheared DNA (50 ng) was end–repaired and
ligated using Quick ligation kit (New England Biolabs) to 27
pmoles of multiplex P1 adaptor and 27 pmoles of one (different for
each ligation) of the bar-coded multiplex P2 double-stranded
adaptors (SOLiD
TM Fragment Library Oligos Kit, Applied
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PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e62522Figure 1. Global overview of eNOS-recruitment by ChIP sequencing and genome-wide changes mediated by estradiol. A) Venn
diagram of regions displaying eNOS-recruitment in the absence (NT) or presence of estradiol (E2). Number of discrete genomic eNOS-recruitment
peaks identified by ChIP-Seq in C27IM_NT and C27IM_E2 (left), LNCaP_NT and LNCaP_E2 (right) using MACS analysis (FDR,0,1 and P value p,1e-5).
Overlap between peaks in NT and E2condition was determined using threshold of 1 nt. B) Length distribution of eNOS peaks in C27 IM_NT, C27 IM_
E2 (left) and LNCaP NT, LNCaP E2 (right). Data are presented as superimposed box plots of peak lenghts for E2 treated (black) or untreated (gray).
Black line is the E2 peaks mean length, gray line is the NT peaks mean length. p,2.2e-16 NT vs E2. C) Pie chart of eNOS-peaks distribution in intra/
extragenic regions (left) or of distance from TSS (right). Numbers in percentage represent min-max values in each category. D) Venn diagram of
MACS-peaks in C27IM_E2 and LNCaP_E2. Overlap between eNOS peaks was determined using threshold of 1 nt. E) Validation by quantitative PCR of
ChIP-Seq eNOS-peaks. eNOS binding was monitored in 9 genomic regions, specificity was assessed in an ‘‘empty’’ region (region without eNOS peaks)
of chromosome 5. Data represent mean+/2SEM of 3 independent experiments. *p,0,05 eNOS_E2 vs eNOS_NT.
doi:10.1371/journal.pone.0062522.g001
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PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e62522Figure 2. Prognostic miRNA signature. A) Supervised cluster analysis of microRNAs profiling (Exiqon Array) for the two groups of patients
defined by recurrence status (Good or Bad prognosis). B) Validation by quantitative real time PCR of differential miRNAs levels in the G1 (Bad
prognosis n=7) and G2 (Good prognosis n=8) groups, *p,0,05 G1 vs G2. C) Differential level of primary transcripts (pri-miR) in G1 (n=7) and G2
(n=8), *p,0,05 G1 vs G2. Data are represented as box plot on a logarithm scale.
doi:10.1371/journal.pone.0062522.g002
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temperature for 10 minutes, purified using the AgencourtH
AMPureH Kit, and nick-translation was performed on non-ligated
39-ends. Finally library molecules were amplified by PCR for 15–
17 cycles and purified using the AgencourtH AMPureH Kit as
described before. Samples were quantified using Qubit dsDNA
HS or BR kits and checked on the Bioanalyzer (Agilent
Technology) using a DNA 1000 chip. To obtain the binding
and the clonal amplification of library fragments on the surface of
sequencing beads, the 8 pooled DNA libraries were added to the
emulsion PCR reaction performed according to the manufactur-
er’s instructions (Applied Biosystems). After amplification, the
emulsion was broken with butanol, beads were enriched for
template positive beads, 39-end extended and covalently attached
onto one sequencing slide, and sequenced using standard settings
on the SOLiD system version 3.5 to produce 50 nucleotide long
reads.
Mapping of Sequencing Data
Mapping of the Color Space sequencing reads to the reference
genome (UCSC Homo sapiens hg19 from UCSC) was performed
with the Lifetech Lifescope 2.5.1 bioinformatics software suite,
after ‘‘a priori’’ error correction with the SAET procedure. The
resulting alignment files (pairwise Input and Experiment) in
standard.bam format were analyzed for peak calling directly with
the MACS software version 1.4.1 [20]. In addition, the.bam
alignments were converted to the.bed format with the bamToBed
bedtools utility and used for peak calling with the SICER analysis
software [21] in order to take into account the heterogeneous
nature of these DNA - protein interactions which may include
quite long areas of interaction. All intersections between MACS
and SICER bed files and genome-wide features was performed
with the bedTools v2.17.0 software suite (http://code.google.
com/p/bedtools/).
Peak Identification
Exploratory data analysis of the sequencing and mapping
results, of the MACS peak quality, of the relative annotation and
further peak calling were performed with the commercial
Integromics SeqSolve bioinformatic software suite. Correlation
of MACS and SICER peaks (Experiment versus Input) with known
NCBI RefSeq gene structure and annotation was performed with
in-house Genomnia perl scripts or with the ChIPpeakAnno
Bioconductor library, version 2.10 [22]. Differential peak analysis
was performed with the SICER-df.sh routine of the SICER
software or with the Bioconductor DiffBind library [23],
complemented by in-house Genomnia perl scripts. Removal of
open chromatin (false positives) regions was performed using ‘‘A
comprehensive collection of signal artifact blacklist regions in the
Table 1. Number of eNOS peaks encompassing 50 kb
genomic regions upstream of annotated pre-miRs.
Down-Regulated miRs
a C27IM NT C27IM E2 LNCAP NT
LNCAP
E2
hsa-miR-34a 1 3 – 3
hsa-miR-4324 2 2 – 1
hsa-let-7b 2 3 – 1
hsa-let-7c – 1 – –
hsa-miR-143 – 1 – –
hsa-miR-4328 3 – – –
hsa-miR-145 – 2 – –
hsa-miR-298 3 5 – 2
hsa-let-7i – – – 2
hsa-miR-491-3p – – – –
hsa-miR-664* – – – –
hsa-miR-1290 – 10 – –
hsa-miR-1908 – 4 – 3
hsa-miR-665 – 2 – –
hsa-miR-3667-5p – – – –
TOTAL 11 33 0 12
Up-Regulated miRs
a C27IM NT C27IM E2 LNCAP NT LNCAP
E2
hsa-miR-10a 2 10 – 7
hsa-miR-15a
has-miR-185
––– –
hsa-miR-197 – 2 – 3
hsa-miR-186 – 1 – –
hsa-miR-183 – 8 – 5
hsa-miR-720 – – 1 –
hsa-miR-221* – – – –
hsa-miR-424 11 1 – –
hsa-miR-7 1 5 1 2
hsa-miR-92a – – – –
hsa-miR-93 – – – –
hsa-miR-744 – – – –
hsa-miR-374a 7 1 – –
hsa-miR-4284 – 6 – 2
hsa-miR-32 – – – –
hsa-miR-16 1 2 – –
hsa-miR-106a 6 1 – –
hsa-miR-17 – – – –
hsa-miR-19a – – – –
hsa-miR-20a – – – –
hsa-miR-106b 1 2 – 1
hsa-miR-18b – – – –
hsa-miR-4289 – – – –
hsa-miR-107 – – – –
hsa-miR-103 4 – 2 –
hsa-miR-15b – – – 1
hsa-miR-205* – – – –
hsa-miR-185 2 4 – 2
Table 1. Cont.
Down-Regulated miRs
a C27IM NT C27IM E2 LNCAP NT
LNCAP
E2
hsa-miR-2115* – – – –
hsa-miR-148b – – – 1
hsa-miR-25 1 – – 1
TOTAL 36 43 4 25
aas shown in G1-PCa cells associated with bad prognosis (see miRs levels in
cluster of Figure 2).
doi:10.1371/journal.pone.0062522.t001
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users/akundaje/rawdata/blacklists/hg19/). Statistical test associ-
ated with sequence features (evaluation of TSS and peak length
mean differences) were evaluated with the Welch Two Sample t-
test in the R version 2.15.1 statistical language. Sequence-linked
statistical analyses, including kernel tag density calculations, were
performed with the appropriate statistical routines and libraries of
the R version 2.15.1 statistical language (http://www.r-project.
org/). Short-read sequencing data and the associated experiment
information have been deposited at the EBI ArrayExpress
Figure 3. Schematic representation of the miR-34a genomic region and eNOS-peaks identified by ChIP-sequencing. A) Integrated
Genome Viewer (IGV 2.1) screenshots showing pri-miR-34a genomic region (TSS is indicated) and eNOS-binding in C27IM, in the presence or absence
of estradiol (E2), identified by ChIP-Seq using two different algorithms MACS and SICER. B) Molecular dissection of orange dashed area indicated in A.
Locations of EREs identified by MatInspector analysis are shown by green circles, eNOS peaks identified by MACS are shown by boxes (blue
C27IM_NT, red C27IM_E2) and primers for ChIP-qPCR by arrows. C) ChIP validation of eNOS peaks and dynamic recruitment of eNOS and ERb in the
regulatory region of pri-miR34a, in the presence or absence of E2. *p,0,05 ERb E2 vs ERb NT;
#p,0,05 eNOS E2 vs eNOS NT.
doi:10.1371/journal.pone.0062522.g003
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PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e62522Figure 4. Effect of Estradiol on miR-34a level and its target SIRT1. A) Normal HUVEC cells, PCa-cells from the G2 and G1 groups (C38IM and
C27IM, respectively) and LNCaP cells were treated with estradiol (E2) for 3 and 6 hours and levels of pri- (left) and mature (right) miR-34a were
analysed by qRT-PCR. Data represent the mean 6 SEM of 4 experiments. *p,0,05 vs NT. B) HUVEC and C27IM cells were treated with E2 and SIRT1
level was assessed by western blot. Upper: representative experiments. Black lines indicate samples run in noncontiguous lanes of the same gel.
Lower: Densitometric analysis of SIRT1 vs HSP70 level is expressed as fold induction +/2E2. Data represent the mean 6 SEM of 3 experiments.
*p,0,05 vs NT. C) SIRT enzymatic activity (left) and corresponding level of protein (right) was evaluated in C27IM cultured for 72 h hours in hormone-
deprived serum before and treated with E2 for 1 h. *p,0,05 vs NT. D) Co-IP of eNOS and SIRT1 in HUVEC and C27IM cells (upper and lower panel,
respectively). IgG served as negative control and cell extract (Input) as positive control. Black lines indicate samples run in noncontiguous lanes of the
same gel. *Lower exposure. E) C27IM cells were cultured for 72 h hours in hormone-deprived serum before treatment with E2 for 2 h15’. Cells were
stained with antibody to SIRT1 (red) and eNOS (green) and analyzed by confocal microscopy. Nuclear co-localization is evidenced by colocalization
mask.
doi:10.1371/journal.pone.0062522.g004
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PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e62522Figure 5. Rescue of estrogen-dependent repression of miR34a by HDACs inhibitors. A) C27IM cells were treated with estradiol (E2) for 3
hours in the presence or absence of inhibitors of deacetylases (TSA, MS275, MC1568), or the SIRT1 inhibitor Sirtinol, or the SIRT1 activator Resveratrol,
added 30 minutes before the hormone. Levels of pri-miR-34a (left) and mature-miR34a (right) were analysed by qRT-PCR. Data represent the mean 6
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sion Number E-MTAB-1204.
SIRT Activity
Enzymatic activity was evaluated with HDAC assay kit
(Upstate) according to manufacturer’s instruction using 40micro-
grams of total extracts.
Confocal Microscopy
Confocal analysis was performed as previously described [1].
Sample were analysed with a Zeiss LSM510 Meta Confocal
Microscope with 63x magnification. For each samples 10
independent fields were analyzed and representative images are
shown. Colocalization mask was obtained by LSM510 software to
produce images containing exclusively colocalized regions.
SEM of 4 experiments. *p,0,05 B) C27IM were transfected with the eNOS dominant negative mutant (S1177A) or empty vector for 48h in presence or
absence of E2 added 1h prior to harvesting. Levels of pri-miR-34a were analysed by qRT-PCR. Data represent the mean 6 SEM of 3 experiments.
*p,0,05 C) C27IM (left), LNCaP cells (middle) and HUVEC (right) were transfected with the eNOS dominant negative mutant (S1177A) or empty vector
for 48 h in presence or absence of E2 added 1 h prior to harvesting. SIRT1 levels were assessed by western blot. Hsp70 served as loading control.
Ratio +/2E2 of SIRT1 level normalized with Hsp70 are indicated. D, E) Confocal analysis of eNOS and HDAC4 (D) and HDAC5 (E) in the presence or
absence of E2 as described in the legend to Figure 4. F) Dynamic recruitment of class I (HDAC3), class II (HDAC4) deacetylases or SIRT1 analyzed by
ChIP in the regulatory region of pri-miR34a in the presence or absence of E2. Arrows represent primers for qPCR as in Figure 3. *p,0,05 SIRT1 E2 vs
SIRT1 NT;
#p,0,05 HDAC3 E2 vs HDAC3 NT; 1HDAC4 E2 vs HDAC 4 NT.
doi:10.1371/journal.pone.0062522.g005
Table 2. Over-represented pathways for overlapping eNOS-peaks in C27IM and LNCaP treated with estradiol.
Name of event Event identifier
a
Total number of genes
involved in the event
Number of genes in
your query mapping
to the event P value
b
Hemostasis REACT_604 478 170 7.91E-10
Developmental Biology REACT_111045 407 166 1.78E-15
Transmembrane transport of small molecules REACT_15518 432 129 0.001395704
Neuronal System REACT_13685 290 125 6.60E-14
Axon guidance REACT_18266 281 119 1.22E-12
Metabolism of lipids and lipoproteins REACT_22258 315 90 0.02380377
Signalling by NGF REACT_11061 222 85 5.60E-07
SLC-mediated transmembrane transport REACT_19118 251 81 0.001023465
Transmission across Chemical Synapses REACT_13477 189 80 7.29E-09
Platelet activation, signaling and aggregation REACT_798 205 78 2.20E-06
Neurotransmitter Receptor Binding And Downstream
Transmission In The Postsynaptic Cell
REACT_15370 136 54 2.01E-05
Cell-Cell communication REACT_111155 137 54 2.57E-05
Signaling by PDGF REACT_16888 122 53 9.92E-07
NGF signalling via TRKA from the plasma membrane REACT_12056 136 53 4.40E-05
Integration of energy metabolism REACT_1505 114 49 3.67E-06
Potassium Channels REACT_75908 99 48 5.51E-08
Signaling by Rho GTPases REACT_11044 125 47 0.000315471
Rho GTPase cycle REACT_11051 125 47 0.000315471
Signaling by NOTCH REACT_299 117 44 0.000482562
L1CAM interactions REACT_22205 109 42 0.000354716
Signaling by EGFR in Cancer REACT_115871 110 41 0.000913295
Integrin cell surface interactions REACT_13552 85 40 1.87E-06
Cell surface interactions at the vascular wall REACT_12051 92 40 2.05E-05
Downstream signal transduction REACT_17025 93 40 2.79E-05
Signaling by EGFR REACT_9417 108 40 0.001209373
Signaling by FGFR REACT_9470 112 40 0.002647301
Downstream signaling of activated FGFR REACT_21272 100 39 0.000428773
Signaling by ERBB2 REACT_115755 102 38 0.00139995
Class B/2 (Secretin family receptors) REACT_18372 88 37 9.91E-05
aas in http://www.reactome.org/ReactomeGWT/entrypoint.html.
bUn-adjusted probability of seeing n or more genes in the event by chance.
doi:10.1371/journal.pone.0062522.t002
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Total RNA purification, including miRNAs, was performed
using the miRNeasy kit (QIAGEN) and samples were stored
immediately at 280uC. RNA quantification and integrity was
assessed using Nanodrop and Agilent 2100 Bioanalyzer. Only
samples with a RNA integrity number (RIN) .8,0 were taken for
analysis. A total of 500 ng RNA from sample and reference was
labelled with Hy3
TM and Hy5
TM fluorescent label, respectively,
using the miRCURY
TM LNA Array power labelling kit (Exiqon,
Denmark) following the procedure described by the manufacturer.
The Hy3
TM-labeled samples and a Hy5
TM-labeled reference RNA
sample were mixed pair-wise and hybridized to the miRCURY
TM
LNA Array version 5
th Generation (Exiqon, Denmark), which
contains capture probes targeting all miRNAs for human, mouse
or rat registered in the miRBASE version 16.0 at the Sanger
Institute. The hybridization was performed according to the
miRCURY
TM LNA array manual using a Tecan HS4800
hybridization station (Tecan, Austria). After hybridization the
microarray slides were scanned and stored in an ozone free
environment (ozone level below 2.0 ppb) in order to prevent
potential bleaching of the fluorescent dyes. The miRCURY
TM
LNA array microarray slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies,
Inc., USA) and the image analysis was carried out using the
ImaGene 9.0 software (BioDiscovery, Inc., USA). The quantified
signals were background corrected (Normexp with offset value 10
[24] and normalized using the global Lowess (LOcally WEighted
Scatterplot Smoothing) regression algorithm. Differential expres-
sion of miRNAs between groups was performed using a t-test one-
tail after which a p value ,0.05 was considered statistically
significant. A total of 52 miRs were used to generate a heatmap
where red and green colors indicate high and low expression
respectively. A two-way supervised clustering analysis was
performed using Pearson’s correlations and Ward’s criteria as a
linkage rule. C27IM cell line was hybridized twice with
correlation=0,92. Microarrays data have been deposited in the
Curie database at http://microarrays.curie.fr/, login username
and password are available upon request.
Mature miRNA and pri-miR Detection
Reverse transcription was performed according to the manu-
facturer’s protocol using TaqMan method (Applied Biosystems,
Foster City, CA, USA). Real-time PCR was performed three times
in duplicate on an ABI Prism 7500 or 7900 HT Sequence
Detection System (Applied Biosystems). Relative amount of each
mature miR or pri-miR was measured as fold change using the
2
2DDCt method (RNU6B or RNU19 and b2actin or GAPDH
served as endogenous control, respectively).
Statistics
Statistical analysis was performed using Prism 2.01 statistical
software (GraphPad). Differences among subject groups were
assessed by 2-tailed Mann-Whitney U test and 1-tailed Student’s t-
test. A 95% confidence interval (P,0.05) was considered
significant. Data are represented as box plots charts (boxes show
medians and upper and lower quartiles of the data and whiskers
indicate minimum and maximum values), as mean 6 SEM or as
fold of induction (+/2 treatment), as indicated in figure legends.
Results
Genome-wide Profile of eNOS-binding Events in Prostate
Cancer Cells
We previously documented that in prostate cancer cells eNOS
translocates to the nucleus in response to estrogen, a process
inhibited by anti-estrogens [5]. Here we show by confocal
microscopy that this estrogen-dependent re-localization is also
efficiently prevented by L-NAME, an inhibitor of eNOS (Figure
Figure 6. Cartoon of proposed eNOS/SIRT1 interplay in prostate cancer cells in response to estrogen.
doi:10.1371/journal.pone.0062522.g006
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eNOS activity, NO production and estrogen signaling.
Our open questions were i. how does eNOS play a role in
prostate cancer under basal conditions or in response to estrogens
and, by extension, in the estrogen-dependent transcriptional
program associated with prostate cancer aggressive phenotype?,
and ii. Does the nuclear eNOS function involve molecular
interactions with proteins able to modify the chromatin structure
and alter the transcriptome in estrogen-responsive prostate cancer
cells? To address these questions chromatin immunoprecipitations
coupled to massive parallel sequencing (ChIP-seq) were performed
before and after treatment with 17b-estradiol (E2, 10
27M) in two
cell lines: i. C27IM cells derived from a primary prostate cancer
with an aggressive phenotype and well characterized by immuno-
phenotype, cytogenetic markers, growth and colony formation,
gene amplification, mRNA gene and miR profile [1,17], and ii.i n
LNCaP cells, a human prostate cell line derived from a lymph
node metastasis [25], thus representative of the ‘‘metastatic’’
phenotype. The retained responsiveness of these cells to sex steroid
hormones, both androgens and estrogens [19,26], renders them an
optimal control for a hormone-responsive primary tumor aggres-
sive but not yet metastatic.
The goal of our study was to identify, in the prostate
microenvironment, the primary transcriptional targets of E2
signaling associated with eNOS. We focused on a short hormonal
treatment (45 min) on the basis of previous studies by us and
others that clearly indicated this timing as optimal for following the
primary and immediate effects of E2-dependent transcription,
prior to the activation of secondary targets [1,6,19,27,28].
eNOS ChIP-seq was conducted and eNOS-associated DNA
regions (peaks) were identified using two algorithms, MACS 1.4.1
(Linux version or as incorporated in the commercial software
SeqSolve
TM from Integromics) and SICER v1.1, to minimize
peak caller bias and to consider the ‘extended’ nature of the
interaction of eNOS/ER complexes with chromatin [20,21].
Differential analysis of called peaks or extended regions (islands)
was also performed with two methods, comparing and intersecting
the results, for the same reasons (see Methods and [22,23,29,30]).
The number of sequencing reads and eNOS-binding events for
each cell line, untreated or exposed to E2, are shown in Table S1.
Under both conditions, the eNOS-containing DNA peaks were
found widely distributed across the genome with conserved
hyperdensity regions, as shown superimposed to the human
chromosome ideograms for both cell lines (Figure S2). This
pattern, reminiscent of the genomic distribution of ERE sites
described by Carroll et al. [31], supports our previous findings of
the existence of eNOS/ER complexes [1,5,6].
We identified by MACS peak call analysis in C27IM and
LNCaP cells, respectively 12,034 and 2,344 eNOS-associated
peaks before E2 treatment, and 57,802 and 34,560 thereafter
(Table S2). Of note, the removal of open chromatin regions
known to generate false positives in ChIP-seq experiments (the so-
called ‘‘ultra-high signal artifact regions’’) left substantially
unchanged the results in terms of peak number: 11,694 and
2,333 in untreated C27IM and LNCaP cells and 57,616 or 34,451
in C27IM and LNCaP cells upon E2 treatment (Table S2 and
Figure 1A) (see Methods and [32].
Clearly upon estrogen treatment the number of peaks increased
significantly (4.8- and 14-fold in C27IM and LNCaP cells,
respectively) indicating a specific hormone-dependent eNOS re-
localization along the genome. A quantitative sequence compar-
ison of eNOS-associated peaks before and after E2 treatment
revealed the existence of overlapping peaks between the two
conditions, (6,805 common peaks in C27IM and 1,368 in LNCaP
cells (Figure 1A). A corresponding overlap of 5,190 and 1,630
genes in C27IM and LNCaP cells, respectively, was also found for
eNOS-peaks associated with the nearest gene as annotated in the
NCBI RefSeq database incorporated in the UCSC Genome
Browser (http://www.ncbi.nlm.nih.gov/RefSeq/), (data not
shown). The overlapping peaks (and associated genes) thus
represent a sub-set of eNOS-bound regions that are not responsive
to estradiol treatment, suggesting eNOS interactions with proteins
others than ER.
On the other end, the majority of peaks are sensitive to E2,
resulting in induction of de-novo eNOS genome binding (50,811
peaks in C27IM and 33,083 in LNCaP) or detachment (4,889
peaks in C27IM and 965 in LNCaP). Of interest, in both cases,
multiple eNOS MACS peaks induced by estradiol exist per gene.
In E2-treated cells most eNOS target genes were bound once or
twice, about 5% were bound 3 times, and about 9% were bound 4
or more times (Table S3). Moreover, E2 stimulation altered the
distribution of eNOS as indicated by significantly increased peak
length after E2 treatment suggesting a DNA-eNOS/ER complex
stabilization following hormonal treatment (Table S2 and
Figure 1B).
Distribution of eNOS-peaks relative to the nearest TSS
obtained using Kernel tag density analysis revealed that i. their
frequency is centered on the TSS and decreases on both sides with
a clear asymmetry toward the intragenic areas (Figure S3A) and
ii. E2 treatment broadened the global area covered by the peaks in
C27IM and, to a less extent, in LNCaP cells, as shown by using a
10.000 bp window, although the peaks showed a significant
enrichment around TSS following E2 stimulus (Fig. S3B).
Remarkably, the global peak distribution in annotated genomic
regions was similar in both experimental conditions (+/2 E2),
with a slight prevalence (53–58%) of peaks localized in extragenic
regions, and the remainder in intragenic regions, in particular
within introns (Figure 1C). As shown in Figure 1D, there was
considerable overlap between peaks induced by E2 in C27IM and
LNCaP cells.
Correlation between number of sites identified by MACS and
SICER in both C27IM and LNCaP cells revealed a substantial
concordance (see Methods), further validated by the results of
ChIP assay shown in Figure S4. For example hTERT, an
estrogen target gene, with several known EREs [1,19,33,34]
displays MACS peaks and E2-increased SICER islands in
correspondence to sites well characterized by ChIP-qPCR
(Figure S4A); pS2 (TFF1), a classical estrogen target gene,
exhibits E2-increased SICER-derived islands at sites amplified by
ChIP-qPCR (Figure S4B); GSTP1, a gene silenced by the ERb-
eNOS complex in the absence of ligand [5] shows MACS peaks in
correspondence to sites amplified by ChIP-qPCR, exclusively in
the unstimulated condition (Figure S4C).
Moreover, the matrix of pairwise correlation depicting DNA
occupancy on the basis of the MACS peak caller score and
coordinates (Figure S5A) as well as the hierarchical cluster
analysis of binding affinity (heatmap) showing affinities for
differentially bound sites calculated from read count data and
MACS peak coordinates (Figure S5B) revealed that binding sites
clustered first in response to E2, and then according the cell type.
A total of 692 E2 vs NT differentially represented peaks (FDR
,0.05) were identified, of these 287 with a positive fold change
and the remainder with a negative one.
Lastly, we validated the eNOS ChIP-Seq data enrichment
observed upon estradiol treatment. The E2 effect was monitored
in C27IM cells, untreated (NT) or E2-treated, using anti-eNOS
antibody and ChIP-qPCR on eight gene promoters previously
identified or derived from microRNA profile analysis (Figure 1E
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correlation between the presence of eNOS-peaks, as emerging
from ChIP-Seq data set upon estrogen treatment (Figure S4 and
data not shown), and the estrogen-induced recruitment of eNOS
onto the same genomic regions as assessed by traditional ChIP-
qPCR. Enrichments were normalized to the absence of antibody
(noAb), or an unrelated antibody (Ab IgG). Specificity of the ChIp-
Seq was ensured using primers amplifying a genomic region within
chromosome 5 lacking eNOS peaks and simultaneously showing
the absence of eNOS recruitment by classical ChIP-qPCR.
Cluster analysis of miRNAs pattern in PCa cells. With
the aim of differentiating lethal and non-lethal prostate cancer and
ultimately improving the clinical outcome of subjects diagnosed
with the disease, and based on the observed eNOS association
with regulatory regions of annotated pri-miR (Table 1), we
combined the ChIP-Seq approach with miR profiling in a subset
of our PCa-derived cell populations [17] using an Exiqon
platform.
The miR profile (Fig. 2A) confirmed the differential miR
expression originally described in prostate cancer histological
samples [12], thus validating again our ex-vivo cellular model
[1,5,17]. In particular, a clear down-regulation of a specific cluster
of miRs (e.g. miR-34a, let-7c, miR-143/miR-145) was observed in
PCa-cells derived from the bad prognosis group, in agreement
with recent reports on the role of these miRs in PCa progression
[11,35,36,37]. These data substantiate the notion that reduced
expression of these specific miRs may be involved in the
acquisition of a more aggressive phenotype.
Since in previous work we had identified a prognostic
transcriptional signature characterized by a wide dysregulation
of several messenger RNAs specifically associated with PCa-cells
with aggressive phenotype [17], miR-array hybridizations were
performed in 8 (out of the 22 originally analyzed) PCa-derived cell
lines, 5 from patients with non-recurrent (Good prognosis, G2)
and 3 with recurrent prostate cancer (Bad prognosis, G1),
including the C27IM cell line subjected to ChIP-Seq analysis.
The comparison between the two groups identified 52 miRs with
significant changes in expression that were used to draw a
clustering analysis that: 1) readily separated the two groups of
patients (Good versus Bad) and 2) clearly showed divergent
expression (down-regulated versus up-regulated) associated with
opposite clinical outcome (Figure 2A). Of interest, a number of
these miRs have previously been reported to show similar down-
or up-regulation in prostate cancer compared to normal prostate
tissue, and some of them (e.g., miR-34a, miR-16, miR-145, miR-
205) have been specifically linked to prostate cancer metastasis
[35,38], again supporting the validity and reproducibility over
time of our ex vivo experimental model. Validation of data derived
from the microarray platform has been performed using qRT-
PCR by evaluating expression of 6 different miRs, either up or
down-regulated, at the mature and primary transcript level
(Figure 2BC). We presumed that differential miRs expression
between G1 and G2 cells could be due to a different
transcriptional regulation, an hypothesis confirmed by the analysis
of the primary transcripts.
Identification and validation of eNOS peaks in the
regulatory regions of miRs associated with opposite
outcome. To determine whether there was a correlation of
the miR profile with data deriving from the ChIP-Seq experi-
ments, we systematically searched for eNOS-bound peaks along
the genomic regions upstream of the annotated pre-miRs
(according to UCSC annotated Hs genome hg19), focusing, in
particular, on those downregulated in the bad prognosis group. Of
note, a consistent number of eNOS peaks, among the downreg-
ulated and upregulated miR clusters, were found 50 kb upstream
of pre-miRs, including major putative transcriptional regulatory
regions (Table 1). Calculating a window of 50 Kb around any
given location in the human genome and a totally random
distribution of the peak population (depleted from the hyper
chippable regions), we would expect 0.195 peaks for C27IM NT;
0.95 peaks for C27IM E2; 0.039 peaks for LNCAP NT and 0.575
peaks for LNCAP E2. Thus, the frequency of peaks upstream of
annotated pri-miRs shown in Table 1 denotes a clear enrichment.
Of interest, although the overall number of peaks was higher in
C27IM as compared to LNCaP cells, addition of E2 further
increased peak numbers suggesting that recruitment onto these
miR regulatory regions is essentially driven by the ligand-activated
estrogen receptor. However we cannot exclude, as alternative
mechanism, the involvement of non-genomic estrogen action
[39,40].
Moreover, this is suggestive of a repressive role mediated by the
ligand-activated eNOS/ER complex at least among the ‘‘tumor
suppressor’’ miRs. The higher frequency of this event in cells
derived from primary tumors is compatible with this being an
early molecular step in the progression of prostate cancer.
Among the various miRs differentially expressed in our cell
populations we focused on miR-34a because it has been recently
demonstrated to be a key negative regulator of prostate cancer
stem cells and metastasis [35].
Figure 3A depicts a cartoon of the pri-miR-34a genomic
region and overlapping eNOS-binding identified by ChIP-Seq
using two different algorithms, MACS and SICER, in C27IM
cells, in the presence or absence of E2. To understand how eNOS
collaborates with ER, we first molecularly dissected a specific
genomic area (delimited in Figure 3A by the dashed area). In
addition, a classical peak profile of the indicated eNOS peaks,
compared to control input, is provided in Figure S6, to certify
their validity. Upon screening for ER consensus sequences by
using MatInspector, ERE motifs were highly ranked as expected,
and 53 EREs (canonical, non-canonical and half site) were found
(Figure 3B). Based on the location of the peaks, specific primers
for ChIP-qPCR were designed to follow the dynamic recruitment
of eNOS and ERb onto the regulatory region of pri-miR-34a,
before and after E2. A consistent occupancy by both proteins of
the regulatory region of pri-miR-34a was observed in basal
condition and was found potentiated upon hormonal treatment,
with the highest enrichment of 3.4- and 8.4-fold for eNOS and
ERb over the untreated (Figure 3C), thus validating the ChIP-
Seq data.
Effects of Estradiol on the Expression of miR-34a and of
its Target SIRT1
Our findings of repression of a miR subset associated with a
PCa aggressive phenotype even in basal condition, and the
increase of eNOS peaks upon estrogen treatment, prompted us to
evaluate whether E2 itself further affected expression of the
constitutively downregulated miR cluster (Figure 2). PCa-cells
belonging to the good and bad prognosis groups (C38IM and
C27IM, respectively), LNCaP and HUVEC cells were treated
with E2 for 3 and 6 hours and level of pri-miR-34a (left) and
mature miR-34a (right) were analysed by qRT-PCR. A significant
repression of both forms of miR-34a was observed in all cell lines
(Figure 4A), more pronounced for the pri-miR than the mature
miR, suggesting estrogen regulation at the level of transcription.
Of interest, in the unstimulated condition, expression of miR34-a
(at both pri-miR and mature level) progressively decreased from
normal endothelial to metastatic cancer cells, in agreement with
recent reports linking miR34-a silencing with the appearance of
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obtained with other miRNAs belonging to the same cluster such as
let-7b, miR-143, miR-145 (data not shown).
Since expression of miR-34a is inversely correlated to that of his
target SIRT1, we asked whether E2 treatment could positively
affect SIRT1 expression and activity. HUVEC and C27IM cells
were treated with E2 versus time. A reproducible induction of
SIRT1 protein and activity by E2 in HUVEC andC27IM cells,
although with a different kinetics was observed (Figure 4B and
C).
On the basis of previous reports [41] and of the ability of SIRT1
to deacetylate (hence activate) eNOS, Co-IPs between eNOS and
SIRT1 and confocal microscopy analysis were performed. A clear
protein-protein interaction was observed in the basal condition in
HUVEC and C27IM cells (Figure 4D). Moreover nuclear
colocalization of both proteins, greatly enhanced upon estrogen
stimulation, was observed by confocal analysis in C27IM cells
(Figure 4E).
Rescue of miR-34a Estrogen-dependent Repression by
SIRT1 and HDACs Inhibitors
With the aim of deepening our insights into the molecular
mechanisms underlying the E2-dependent negative regulation of
miR-34a, we treated C27IM cells with several inhibitors: Sirtinol,
specific for SIRT1, Trichostatin A (TSA) specific for class I and IIa
mammalian histone deacetylases (HDACs), but not class III
HDACs (i.e., Sirtuins) [42], or MS275 and MC1568 specific for
HDACs I and IIa, respectively. The SIRT1 activator, Resveratrol,
was also included as control. Figure 5A shows that Sirtinol was
effective in preventing the E2-mediated silencing of miR-34a, both
at mature and pri-miR levels. MC1568 also rescued miR-34a
expression although to a lower extent, whereas MS275 and TSA
appeared to be the least efficient As one would expect, Resveratrol
was totally ineffective in rescuing the estrogen-dependent miR-34a
silencing.
To assess the specificity of our findings and to prove the primary
role played by eNOS together with ERb in mediating this
transcriptional regulation, we evaluated miR-34a levels upon
overexpression of a dominant negative eNOS mutant, S1177A [4],
in C27IM, before and after E2. As expected from the results
shown in Fig. 5A, transfection of empty vector did not affect the
E2-dependent inhibition of pri-miR34a. On the other hand, the
eNOS mutant rescued the E2-dependent pri-miR34a repression
(Figure 5B) with the consequent relief of the estrogen-dependent
SIRT1 induction in C27IM as well as in LNCaP and HUVEC
cells (Figure 5C). Of note, in the presence of dn-eNOS we
observed a stabilization of SIRT1 possibly due to partial reduction
of pri-miR34a in the absence of estrogen (Figure 5B). In all cases,
however, estradiol treatment, which usually increases the intra-
cellular levels of NO, failed to induce SIRT1 expression in this
condition. These results reveal the existence of a feedback loop
whereby, upon estrogen, SIRT/eNOS regulates transcription of
miR-34a which in turn modulates SIRT1 expression.
Overall these findings are highly suggestive of a direct
involvement of NAD+-dependent deacetylases such as SIRT1,
and to a less extent, of histone class IIa deacetylases such as
HDAC4 or HDAC5. To investigate the mechanism by which
these molecules participate in the miR-34a estrogen-dependent
transcriptional silencing, we performed confocal analysis and ChIP
assays in the presence or absence of E2 and analyzed their
recruitment onto a long genomic regulatory region upstream of
the miR-34a promoter. Confocal microscopy revealed that E2
treatment increased the co-localization of HDAC4/eNOS and
HDAC5/eNOS (Figure 5D, E). Moreover, since HDAC4 and 5
do not bind directly DNA but acquire this property through their
interaction with HDAC3 [43,44], ChIP assays were performed
with antibodies to HDAC 3 and 4 as well as SIRT1 (Figure 5F).
Occupancy of the miR-34a promoter was observed essentially only
after hormonal stimulation, HDAC4 and SIRT1 exhibiting the
highest enrichment (with a maximum of 8.4- and 10.6-fold over
control, respectively). These data substantiate the presence of
hetero-complexes suggesting that the interplay among members of
class I, IIa and III contributes to the estrogen-dependent
repression of miR-34a in aggressive prostate cancer cells.
Discussion
In this study we have generated a genome wide profile of
eNOS-DNA associations that has revealed an unexpected very
wide distribution of the protein. Since eNOS is not per se a DNA-
binding protein nor a classical transcription factor, this observation
suggested to us its association with a variety of chromatin-binding
partners. Indeed, we show that eNOS can interact with the
genome in a dual-fashion, either by forming complexes with
transcription factors that bind specific DNA motifs, or by
associating with proteins, such as histone deacetylases, present
over large genomic regions. Evidence that eNOS contributes to
transcriptional regulation by forming complexes with ERb and
HIFs, detectable on chromatin or in solution, has been provided
by our previous work [1].
The existence, under basal conditions or in response to
estrogen, of a variety of putative eNOS-targeted genes distributed
genome-wide, suggests a key role for eNOS in PCa (Figure 1A
and D). In agreement with that, gene ontology analysis of over-
represented pathways shared by C27IM and LNCaP cells
exclusively upon estrogen stimulation (Table 2) shows a series
of gene pathways involving eNOS in PCa progression, thus
revealing an unprecedented scenario for eNOS involvement at the
chromatin level in tumorigenesis. Recent data [45] have in fact
provided evidence supporting eNOS-targeted therapy in clinical
oncology.
These findings are extremely novel with respect to the more
established cytoplasmic localization and role attributed to eNOS
[46,47], and reinforce the specific eNOS nuclear function in
aggressive prostate cancer proposed by our previous in vivo studies
on TissueMicroArrays from PCa patients. In fact we have
demonstrated that higher expression of eNOS, cytoplasmic and
nuclear, was, together with ERb and HIFs, the most relevant
indicator of adverse clinical outcome within a prognostic
expression signature [1,17].
In investigating the effects of estrogen on the transcriptional
regulation involving eNOS in PCa we have focused on two genes:
miR-34a, whose expression is decreased in PCa, and one of its
targets, the class III deacetylase SIRT1 [48,49]. One mechanism
by which miR-34a expression decreases in cancer is through
aberrant CpG methylation of its promoter [50]. However, by
immunoprecipitation of methylated DNA [5], we observed a low/
intermediate level of methylation in 4 PCa-derived cell lines
(including C27IM) compared with LNCaP cells (data not shown).
Thus methylation does not appear to be the only mechanism
responsible for miR-34a silencing, at least in PCa cells. We indeed
have previously provided evidence of an alternative silencing
mechanism attributable to the eNOS/ERb complex activated by
E2 [5].
With regard to SIRT1 it is known that its expression is increased
in a variety of human cancers including PCa [48,51], suggesting a
critical role of this protein in tumorigenesis [49]. The crosstalk
between SIRT1 and eNOS is determined by the deacetylation of
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domain of eNOS that is, in turn, activated by SIRT1 [41]. This
effect is generally considered part of the protective and beneficial
function of the SIRT1/eNOS axis. As a consequence of its
important biological properties SIRT1 has emerged as a drug
development target for treating age-dependent diseases. It appears,
however, that biologically its main function resides in the optimal
balancing between aging and cancer [16].
Based on our results we propose the following model: in
aggressive PCa an abnormal estrogen stimulation, resulting from
the decrease of androgen in favor of estrogen during aging [52],
results in almost complete silencing of miR-34a. As a consequence,
there is a rapid increase in SIRT1 expression that determines, in
turn, activation of eNOS. The resulting positive feedback on both
proteins (see cartoon in Figure 6) further represses transcription
of miR34-a. Silencing of this miR has already been linked to
promotion of prostate cancer stem cells and metastasis [35]. Our
contribution reveals the molecular mechanisms responsible for this
phenomenon, i.e. its dependence on the transcriptional repressive
function of eNOS-containing complexes. Genetic inhibition of
eNOS by overexpression of a dominant negative eNOS mutant,
interrupts the eNOS/miR-34a/SIRT1 pathway, thus validating
our hypothesis (Figure 5B,C).
Moreover, the estrogen-dependent repression of miR-34a is
prevented by treatment with HDAC inhibitors (Figure 5A), the
SIRT1 specific inhibitor Sirtinol being the most efficient, revealing
a tight link between SIRT1 and eNOS through the SIRT1
regulator, miR-34a [15]. The effects obtained with the HDAC
inhibitors favors the view of eNOS as a critical factor participating
in chromatin remodeling complexes in association with different
classes of histone deacetylases (Figure 5F).
Of interest, the small polyphenolic compound, Resveratrol, a
classical SIRT1 activator, did not rescue miR-34a expression
(Figure 5A). This may be explained by an additive effect of
Resveratrol on the eNOS/NO pathway given its known role on
SIRT1 activation and NO production. On the other end,
Resveratrol has structural similarity to the synthetic estrogen
diethylstilbestrol and acts as an estrogen receptor partial agonist
[53,54]. These features may provide an alternative interpretation
of our data showing that in the presence of this ER ligand, the
repression of miR-34a transcription induced by eNOS/ERb
complex cannot be reversed.
In conclusion, we have documented the genome-wide
existence of a considerable number of eNOS-DNA associations
that define transcriptional active regions, as well as a significant
downregulation of a cluster of miRs, among which miR-34a, in
PCa cells associated with adverse outcome (G1 cells). These
results have revealed a molecular link between eNOS, SIRT1
and miR-34a in the prostate microenvironment. We have also
identified, in the same context, novel eNOS-targeted genes (e.g.
miRs and their targets) in both untreated and E2-treated cells, a
finding that suggests that eNOS may participate in the
regulation of large gene sets, thus fulfilling a novel molecular
role at chromatin level.
Supporting Information
Figure S1 Nuclear colocalization of ERb and eNOS.
C27IM cells were cultured for 72 hours in hormone-deprived
serum before treatment with E2 or the eNOS inhibitor L-NAME
alone or in combination. Cells were stained with antibody to
eNOS or ERb and examined by confocal microscopy. Nuclei were
stained with TOPRO3. Images were digitally transformed to
quantify the mean fluorescence intensity on selected areas for
single eNOS- or ERb- positive cells. The resulting histograms
indicate the presence or the accumulation of eNOS or ERb
proteins in the nuclei of prostate cells, expressed as fold induction
relative to control (Nuclear localization index). Data represent the
mean 6 SEM of two indipendent experiments, each performed in
duplicate. p,0,05 * vs control, # vs E2.
(TIF)
Figure S2 Human chromosome ideograms of eNOS
peaks in presence or absence of estradiol. UCSC Genome
Graphs illustrating the localization and density of eNOS-peaks in
PCa cells: C27IM (A) and LNCaP (B); untreated (NT, blue dots) or
treated with Estradiol (E2, red dots).
(TIF)
Figure S3 Kernel Tag density analysis of eNOS-peaks
distribution relative to the nearest TSS. A) Window of
150.000 bp from TSS in C27IM_NT, C27IM_E2, LNCaP _NT,
and LNCaP_E2 cells. B) Window of 10.000 bp from TSS:
C27IM_NT versus C27IM_E2 (left) and LNCaP NT versus
LNCaP E2 (right). Green dashed line: untreated samples (NT), red
line: estradiol samples (E2). Welch Two Sample t-test of TSS
distance C27IM E2 vs C27IM: p=0.001166; LNCAP E2 vs
LNCAP NT: p=0.02002.
(TIF)
Figure S4 Validation of ChIP-Seq eNOS peaks by MACS
and SICER algorithms in C27IM and LNCaP cells, in the
presence or absence of E2. Peaks visualization was obtained
using Integrated Genome Viewer (IGV 2.1). Screenshots of ChIP-
Seq eNOS peaks surrounding hTERT (A), pS2 (TTF1, B) and
GSTP1 (C) regulatory genomic regions are shown. Primers used
for ChIP-qPCR validation are indicated with dashed orange lines.
(TIF)
Figure S5 A) Correlation heatmap using peak caller score
between C27IM and LNCaP cells in the presence or absence of
E2. B) Hierarchical cluster analysis of binding sites (affinity
analysis) in C27IM and LNCaP cells with or without E2.
(TIF)
Figure S6 Screenshot showing the pri-miR-34a genomic
region and ChIP-Sequencing data. Graphic representation of
the alignement of reads derived from eNOS-immunoprecipitated
and control input. MACS peaks in immunoprecipitated and
control samples in C27IM untreated (NT) or treated with estradiol
(E2) are shown in upper Panel, corresponding reads in lower
Panel. eNOS-positive peaks corresponding to Figure 3B are
indicated by red (C27IM_E2) and blue boxes (C27IM_NT).
Transcription tracks from the ENCODE project: 1) overlayed
H3K27Ac track shows where modification of histone proteins is
suggestive of enhancer and, to a lesser extent, other regulatory
elements; 2) DNase Clusters track shows regions where the
chromatin is hypersensitive to DNase I, e.g regulatory regions and
promoters); 3) Txn Factor ChIP track shows DNA regions where
transcription factors bind as assessed by chromatin immunopre-
cipitation with antibodies specific to the transcription factor
followed by sequencing of the precipitated DNA (ChIP-seq).
(TIF)
Table S1 ChIP-Seq mapping for each sample.
(DOC)
Table S2 Genome-wide determination of regions displaying
eNOS-recruitment in the absence or presence of estradiol (MACS
analysis).
(DOC)
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